Alnylam Pharmaceuticals, Inc. (ALNY) · wyniki II kw. 2026 i wycena

Przy wzroście 20,0% rocznie (3-letni wzrost przychodów) wartość godziwa z modelu to $191.02 na akcję — kurs jest o 17% poniżej niej. Obecna cena zakłada wzrost o 17,1% rocznie.

1. Główny temat

   The company stated it remains highly confident in its path to achieving TTR leadership due to improved understanding of demand dynamics and a favorable competitive landscape.

   Cytat ze źródła

   “Overall, we remain highly confident in our path to achieving TTR leadership. These learnings have sharpened our understanding of demand dynamics while also reinforcing our confidence in the fundamental drivers of sustainable growth. The momentum of the business, coupled with an increasingly favorable competitive landscape, reinforce our conviction in achieving our long-term ambitions.”

2. Prognoza ↓

   2026 revenue guidance was lowered after reassessing the first few quarters in the U.S.

   Cytat ze źródła

   “As Jeff will describe shortly, we are lowering our 2026 revenue guidance today to reflect a better understanding with hindsight of the first few quarters of our U.S.”

3. Prognoza

   CARDIO-TTRansform results now suggest fewer branded competitors in first-line and stabilizer progressive segments.

   Cytat ze źródła

   “Second, based on the CARDIO-TTRansform study top line results, we now anticipate fewer branded ATTR-CM competitor in both the first-line and stabilizer progressive segments.”

Script and answers carried a similar tone, so the script's message held up under questioning.

Zdania, które wpłynęły na ton

“Second, the fundamentals of our TTR business are strong, and they include AMVUTTRA's compelling clinical profile and label, the strong access that we established at launch, which continues to improve,...”

“Double-clicking on our Q2 TTR performance in the U.S., underlying demand was exceptionally strong, increasing by $129 million in the quarter, more than doubling the demand growth achieved in Q1.”

“We are already seeing early progress from these efforts with accelerated growth in new AMVUTTRA prescribers during the second quarter, we believe we are in the early stages of that...”